Medtronic stock steadies ahead of earnings as analysts see double-digit growth
Published on 08/31/2026 at 20:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medtronic plc (ISIN IE00BTN1Y115) stock is trading close to $91 as investors look toward the company’s upcoming first-quarter fiscal 2027 earnings report, where analysts are calling for double-digit growth in both revenue and earnings per share as of August 31, 2026. This places the shares at a valuation that reflects cautious optimism ahead of a potential move on earnings.
Upcoming earnings set growth test
According to an earnings preview published on August 31, 2026, analysts expect Medtronic to report adjusted earnings per share of $1.39 for the first quarter of fiscal 2027, which would represent a 9.5% increase from the prior-year period. The same preview notes that Wall Street is modeling revenue of $9.55 billion in the quarter, implying year-over-year growth of 11.3% in Medtronic’s top line. These estimates position the next set of results as a test of whether the company can sustain the strongest annual growth trend it has seen in a decade.
Medtronic’s prior quarter, which ended in April 2026, provides important context for these expectations. In that quarter, the company delivered adjusted earnings per share of $1.55 on revenue of $9.80 billion, beating consensus forecasts on both metrics and marking annual revenue growth of 8.4%, its highest rate in ten years. The upcoming report will therefore show whether the momentum seen in the April 2026 quarter can be extended into the new fiscal year or whether growth moderates toward historical averages.
Analyst consensus and valuation backdrop
The same August 31, 2026 preview highlights that the analyst community maintains a Buy consensus on Medtronic stock, with 29 analysts publishing ratings and targets on the shares. Their mean price target stands at $98.84, which is 8 percent higher than the current share price level referenced at $91.23. That gap between the average target and the market price reflects expectations for further upside if the company delivers on its earnings and revenue projections.
On valuation, the preview notes that Medtronic shares are changing hands at 15.3 times forward earnings, a multiple that sits in line with many large-cap medical technology peers but leaves room for re-rating if growth continues to accelerate. Options positioning around the upcoming earnings report also provides a quantitative view of market expectations. An implied-move analysis for Medtronic’s September 1, 2026 earnings event shows that options prices are embedding a move of plus or minus 5.1 percent in the share price around the release, modestly above the company’s average earnings-related move of plus or minus 4.5 percent over the last decade. Taken together, the valuation and options data suggest that investors are prepared for a meaningful reaction to the new information but not an extreme surprise.
Several analyst teams have recently adjusted their price targets for Medtronic to reflect the improved growth outlook. One summary of these changes notes that one firm lifted its target from $100 to $110, while another raised its target from $101 to $114, with both maintaining positive recommendations on the shares. These higher targets contribute to the $98.84 average and underscore confidence that Medtronic’s new technologies can support mid- to high-single-digit revenue growth beyond the current year.
Momentum from recent quarterly performance
Beyond the April 2026 quarter, investors are also looking at Medtronic’s broader performance trend in recent periods. An analysis of the company’s latest reported third quarter, which preceded the April 2026 fiscal year-end, shows that Medtronic delivered 6 percent organic revenue growth, the strongest in ten quarters. In that period, adjusted earnings per share came in at $1.36, exceeding the company’s own guidance range by $0.03. This record of beating guidance on earnings while accelerating revenue growth has helped restore confidence in Medtronic’s ability to execute after several years of more muted expansion.
Within that strong quarter, some segments stood out for exceptional growth. The Cardiac Ablation Solutions business posted 80 percent year-over-year growth, highlighting the demand for advanced heart rhythm management technologies. Such segment-level performance suggests that Medtronic’s innovation pipeline is contributing materially to overall company growth, which is particularly important in the context of an industry where reimbursement pressures and competition can weigh on legacy product lines. As investors evaluate the upcoming quarter, they will be watching whether high-growth segments like Cardiac Ablation Solutions continue to deliver outsized gains or whether growth becomes more evenly distributed across the portfolio.
Sector context and expectations
The broader health care sector backdrop is also relevant for Medtronic stock. Sector-focused benchmarks have generated double-digit gains year-to-date in 2026, driven by renewed interest in defensive growth names and companies tied to structural themes like aging populations and chronic disease management. In that context, Medtronic’s year-to-date return of negative 3.4 percent, compared with gains of 13.1 percent for a broad-market index and 11.0 percent for a health care sector ETF, positions the stock as a relative laggard despite its improving earnings profile. This underperformance amplifies the significance of the upcoming results: a solid report could help close the performance gap, while any disappointment might reinforce the market’s cautious stance.
The options-implied earnings move of plus or minus 5.1 percent provides one quantified benchmark for potential post-earnings volatility. If Medtronic meets or exceeds the $1.39 EPS and $9.55 billion revenue trajectories, and reiterates or lifts its fiscal 2027 guidance, a move toward or beyond the $98.84 average price target would be consistent with the current positioning. Conversely, if the company reports weaker-than-expected growth, particularly in high-profile segments or geographies, the valuation multiple of 15.3 times forward earnings could face renewed pressure as investors reassess the long-term growth rate they are willing to pay for.
Go deeper
More detail on Medtronic stock’s earnings setup and valuation metrics is available in an in-depth earnings preview that outlines consensus estimates, recent segment performance, and analyst target changes ahead of the September 1, 2026 report.
Robotic surgery and AI platforms as product drivers
A key part of the Medtronic investment story now centers on its portfolio of robotic surgery systems and artificial intelligence-enabled platforms. The earnings preview emphasizes that the upcoming report will test whether these next-generation technologies can continue to translate into sustained financial outperformance. In areas such as surgical robotics, Medtronic has been building integrated systems designed to enhance precision, reduce complications, and shorten recovery times, which can be attractive to hospitals seeking efficiency gains and better patient outcomes.
Artificial intelligence is also increasingly embedded across Medtronic’s offerings, from diagnostic tools that support early detection of disease, to decision-support systems that assist clinicians during procedures. These AI-powered platforms can help standardize care, reduce variability, and improve throughput in busy clinical environments. As the company scales these technologies, investors will be looking for evidence that they contribute meaningfully to revenue growth and margin resilience, particularly in high-growth segments like Cardiac Ablation Solutions and in newer categories where Medtronic is competing against both established device makers and emerging digital health players.
Medtronic stock and current trading level
Heading into the September 1, 2026 earnings release, Medtronic stock is referenced at a current trading level of $91.23, based on recent market data as of late August 2026. That price sits below the $98.84 mean analyst target, outlining the 8 percent upside that consensus sees if the company delivers on its growth trajectory. With options pricing implying a move of plus or minus 5.1 percent on earnings and the shares valued at 15.3 times forward earnings, the upcoming report is likely to be a key catalyst for whether Medtronic’s valuation converges toward analyst expectations or remains constrained by lingering concerns over execution and competition.
Fact box
Company: Medtronic plc
ISIN: IE00BTN1Y115
Ticker: MDT
Exchange: New York Stock Exchange (primary listing via Medtronic’s US-traded shares)
Sector / Industry: Health care equipment and medical technology
Index membership: S&P 500
